Piper Sandler Reiterates Overweight on NovoCure, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Jason Bednar has reiterated an Overweight rating on NovoCure (NASDAQ:NVCR) and increased the price target from $25 to $28.
April 10, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on NovoCure and raised the price target from $25 to $28.
The reiteration of an Overweight rating combined with an increase in the price target by a reputable analyst firm like Piper Sandler typically signals a strong bullish sentiment towards the stock. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100